Denmark is at the forefront of integrating artificial intelligence within structured regulation, recently launching a new AI ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

A new, better Ozempic? Scientists from the University of Copenhagen say they have developed a drug that decreases appetite ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...